- Home
- IVZ vs BMRN Comparison
IVZ vs BMRN Comparison
Compare IVZ & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IVZ | BMRN |
|---|---|---|
| Founded | 1935 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 10.4B |
| IPO Year | 2014 | 1999 |
Fundamental Metrics
Financial Performance| Metric | IVZ | BMRN |
|---|---|---|
| Price | $26.05 | $58.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 18 |
| Target Price | $27.43 | ★ $88.22 |
| AVG Volume (30 Days) | ★ 4.4M | 2.1M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.51 | ★ 0.54 |
| Revenue | ★ $5,314,100,000.00 | $1,313,646,000.00 |
| Revenue This Year | N/A | $15.02 |
| Revenue Next Year | $5.83 | $12.23 |
| P/E Ratio | ★ $50.75 | $106.20 |
| Revenue Growth | 2.98 | ★ 17.62 |
| 52 Week Low | $15.61 | $49.26 |
| 52 Week High | $29.82 | $66.28 |
Technical Indicators
Market Signals| Indicator | IVZ | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 39.99 | 63.28 |
| Support Level | $24.96 | $54.24 |
| Resistance Level | $27.46 | $61.92 |
| Average True Range (ATR) | 0.99 | 1.42 |
| MACD | -0.36 | 0.23 |
| Stochastic Oscillator | 9.82 | 78.95 |
Price Performance
Historical ComparisonAbout IVZ Invesco Ltd
Invesco provides investment-management services to retail (70% of managed assets) and institutional (30%) clients. At the end of November 2025, the firm had $2.154 trillion in assets under management spread among its equity (62% of AUM), balanced (3%), fixed-income (20%), alternative investment (6%), and money market (9%) operations. Passive products account for close to half of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 31% of its AUM sourced from Europe, Africa, and the Middle East (16%) and Asia (15%).
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.